RalphVBocciaMD

Oncology • Bethesda, MD

Center for Cancer and Blood Disorders

Join to view full profile

Dr. Boccia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Boccia's full profile

Already have an account?

Office
6410 Rockledge Dr
Suite 660
Bethesda, MD 20817
Phone+1 301-571-0019

Fax+1 301-571-0988
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1980 - 1981
University of Minnesota Medical School

Certifications & Licensure

CA State Medical License 1980 - Present
MD State Medical License 1983 - 2024
DC State Medical License 2002 - 2024
NJ State Medical License 2015 - 2019
MN State Medical License 1978 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
Top Doctors:Washington DC Area Castle Connolly, 2012
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Top MD Consumers Checkbook
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
Unknown status
Phase 2
A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 2
A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome Start of enrollment: 2004 Aug 01
Terminated
Phase 2
A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting Start of enrollment: 2006 Aug 01
Terminated
Phase 4
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Completed
Phase 2
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Start of enrollment: 2009 Feb 01
Completed
Phase 2
Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia Start of enrollment: 2009 Apr 01
Terminated
Phase 2
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
Completed
Phase 3
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment Start of enrollment: 2012 Jul 01
Terminated
Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Start of enrollment: 2014 Apr 01
Recruiting
Phase 3
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Start of enrollment: 2014 Jul 14
Completed
Phase 3
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01
Completed
Phase 3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Start of enrollment: 2015 Dec 01
Completed
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Start of enrollment: 2017 Feb 15
Completed
Phase 1
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Start of enrollment: 2020 Jun 12
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Effect of Ferric Carboxymaltose Versus Low-Dose Intravenous Iron Therapy and Iron Sucrose on the Total Cost of Care in Patients with Iron Deficiency Anemia: A US Claim...
Winghan Jacqueline Kwong, Kevin Wang, Peng Wang, Ralph Boccia> ;Drugs - Real World Outcomes. 2024 Mar 19
2 citations
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
Dipti Patel-Donnelly, Timothy Larson, Ralph Boccia, Vivian J M Cline, Adrija Mamidipalli, Jingmin Liu, Alev Akyol, Yasenchak, C. A., Jonathan W Friedberg, Rodolfo Bord...> ;Blood. 2024 Feb 29
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase...
Mehdi Hamadani, Morton Coleman, Ralph Boccia, Juraj Duras, Martin Hutchings, Pier Luigi Zinzani, Raul Cordoba, Mariana Bastos Oreiro, Vanessa Williams, Huiqing Liu, Mi...> ;Hematological Oncology. 2023 Dec 1
4 citations
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.
James R Berenson, Daisy Martinez, Tahmineh Safaie, Ralph Boccia, Honghao Yang, Mehdi Moezi, Stephen Lim, Gary Schwartz, Shahrooz Eshaghian, Regina Swift, Benjamin M Ea...> ;British Journal of Haematology. 2023 Mar 1
12 citations
Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
Ralph Boccia, Jeffrey Crawford, Matti Aapro, Glaspy, J.> ;The Oncologist. 2022 Aug 5
3 citations
Relationship Between Initial Parenteral Iron Therapy Dosing and Treatment Effectiveness: A Real-World Retrospective Analysis.
Chris LaVallee, Isha Bansal, Shilpa Kamdar, Winghan Jacqueline Kwong, Ralph V Boccia> ;Journal of Blood Medicine. 2022 Jan 1
4 citations
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controll...
Tamta Makharadze, Ralph V. Boccia, Anna Krupa, Nicole Blackman, David H. Henry, Jeffrey A. Gilreath> ;American Journal of Hematology. 2021 Nov 19
13 citations
Immune thrombocytopenia.
James Bussel, Nichola Cooper, Ralph Boccia, Francesco Zaja, Adrian Newland> ;Expert Review of Hematology. 2021 Nov 1
4 citations
Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study.
Darla K. Liles, Nirmish Shah, Brigid Scullin, Victor R. Gordeuk, Wally R. Smith, Julie Kanter, Maureen Achebe, Ralph V. Boccia, Shelley E. Crary, Walter K. Kraft, Nata...> ;British Journal of Haematology. 2021 Oct 5
6 citations
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma.
Shaji Kumar, Alan Fu, Ruben Niesvizky, Sundar Jagannath, Ralph V. Boccia, Noopur Raje> ;Blood Advances. 2021 Jan 26
8 citations
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak, Veena Charu, Roger M. Lyons, Jack Aiello, Kimberly Bogard, Renda H. Ferrari, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Nov 1
36 citations
Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
Ralph V. Boccia, Nichola Cooper, Waleed Ghanima, Michael Boxer, Quentin A. Hill, Michelle Sholzberg, Michael D. Tarantino, Leslie Todd, Sandra Tong, James B. Bussel> ;British Journal of Haematology. 2020 Jul 23
8 citations
Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorecta...
Gregory J. Tsongalis, M Rabie Al Turkmani, Michael Suriawinata, Michael J Babcock, Kristi Mitchell, Yi Ding, Lisa M. Scicchitano, Adrian Tira, Lela Buckingham, Sara At...> ;American Journal of Clinical Pathology. 2020 Jul 7
1 citations
Importance of Initial Complete Parenteral Iron Repletion on Hemoglobin Level Normalization and Health Care Resource Utilization: A Retrospective Analysis
Chris LaVallee, Patrick Cronin, Isha Bansal, Winghan Jacqueline Kwong, Ralph V. Boccia> ;Pharmacotherapy. 2019 Oct 1
93 citations
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Jared Weiss, Tibor Csoszi, M. Maglakelidze, Robert Hoyer, J.T. Beck, M. Domine Gomez, A. Lowczak, Raid Aljumaily, C.M. Rocha Lima, Ralph V. Boccia, Wahid Hanna, Petros...> ;Annals of Oncology. 2019 Oct 1
15 citations
Efficacy and Safety Results From a Phase 1b/2, Multicenter, Open-Label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Parameswaran Hari, Claudia E. Paba-Prada, Peter M. Voorhees, John Frye, Yu-Lin Chang, Philippe Moreau, Jeffrey A. Zonder, Ralph V. Boccia, Kenneth H. Shain> ;Leukemia Research. 2019 Aug 1
21 citations
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study).
Philippe Moreau, Shaji Kumar, Ralph V. Boccia, Shinsuke Iida, Hartmut Goldschmidt, Kim Cocks, Andrew Trigg, Anita Zahlten-Kumeli, Emre Yucel, Sumeet Panjabi, Meletios ...> ;Leukemia. 2019 May 15
36 citations
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
A. Keith Stewart, Amrita Krishnan, Seema Singhal, Ralph V. Boccia, Manish R. Patel, Ruben Niesvizky, Asher Chanan-Khan, Sikander Ailawadhi, Jochen Brumm, Kirsten Mundt...> ;Blood Cancer Journal. 2019 Feb 4
28 citations
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR
Meletios A. Dimopoulos, David S. Siegel, Darrell White, Ralph V. Boccia, Karim Iskander, Zhao Yang, Amy S. Kimball, Khalid Mezzi, Heinz Ludwig, Ruben Niesvizky> ;Blood. 2019 Jan 10
9 citations
Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
Ralph V. Boccia, Robert B Geller, Neil J. Clendeninn, Thomas Ottoboni> ;Future Oncology. 2019 Jan 1
15 citations
Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United Sta...
Michael R. Grunwald, Brady L. Stein, Ralph V. Boccia, Stephen T. Oh, Dilan Paranagama, Shreekant Parasuraman, Philomena Colucci, Ruben A. Mesa> ;Clinical Lymphoma, Myeloma & Leukemia. 2018 Dec 1
492 citations
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Dirix, István Takács, Guy Jerusalem, Petros Nikolinakos, Hendrik Tobias Arkenau, Andres Forero-Torres, Ralph V. Boccia, Marc E. Lippman, Robert Somer, Martin Smaka...> ;Breast Cancer Research and Treatment. 2018 Oct 23
21 citations
Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
Ruben A. Mesa, Ralph V. Boccia, Michael R. Grunwald, Stephen T. Oh, Philomena Colucci, Dilan Paranagama, Shreekant Parasuraman, Brady L. Stein> ;Clinical Lymphoma, Myeloma & Leukemia. 2018 Sep 1
8 citations
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
John D. Hainsworth, David M. Waterhouse, Kent C. Shih, Ralph V. Boccia, Victor M. Priego, Michael McCleod, Fred J. Kudrik, Reed Brian Mitchell, Howard A. Burris, F. An...> ;Lung Cancer. 2018 Apr 1
9 citations
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
Jeffrey L. Vacirca, Dennis Caruana, George Calcanes, Michael Mosier, Ralph V. Boccia, Ali McBride> ;Future Oncology. 2018 Feb 9
Join now to see all

Journal Articles

Carfilzomib vs Bortezomib in Patients with Multiple Myeloma and Renal Failure: A Subgroup Analysis of ENDEAVOR
Ruben Niesvizky, David Siegel, Ralph Boccia, Blood

Abstracts/Posters

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...
Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of Parenteral Iron Therapy on Hemoglobin Normalization: A Retrospective Analysis
Ralph Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N...
Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia
Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlle...
Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients
Ralph Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Severe Hypophosphatemia in Patients with Cancer Following IV Iron Treatment: Results from a Large Comparative Trial
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

MediMergent Leverages Patient-Centric Real-World Data and Evidence Platform to Capture the Voice of the Patient in National Cancer TrialMarch 29th, 2023
Fostamatinib More Effective Earlier in Treatment for Immune ThrombocytopeniaDecember 1st, 2020
VerdePharmHealth and Altopa Enter into Exclusive Partnership Agreement for Patient-Centric CBD FormulationsSeptember 15th, 2020
Join now to see all